Janux Therapeutics (JANX) Competitors $23.56 -0.45 (-1.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.59 +0.03 (+0.13%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. TGTX, NUVL, CRSP, RYTM, LNTH, AXSM, TLX, PCVX, MRUS, and CYTKShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), Merus (MRUS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Its Competitors TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Lantheus Axsome Therapeutics Telix Pharmaceuticals Vaxcyte Merus Cytokinetics Janux Therapeutics (NASDAQ:JANX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Does the media refer more to JANX or TGTX? In the previous week, TG Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 9 mentions for TG Therapeutics and 5 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.42 beat TG Therapeutics' score of 1.14 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, JANX or TGTX? TG Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M131.64-$68.99M-$1.36-17.32TG Therapeutics$329M16.90$23.38M$0.24145.92 Is JANX or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to Janux Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -9.29% -8.89% TG Therapeutics 10.13%18.88%7.05% Do analysts recommend JANX or TGTX? Janux Therapeutics presently has a consensus price target of $91.89, suggesting a potential upside of 290.02%. TG Therapeutics has a consensus price target of $43.80, suggesting a potential upside of 25.07%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Janux Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk and volatility, JANX or TGTX? Janux Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Do institutionals & insiders have more ownership in JANX or TGTX? 75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 8.1% of Janux Therapeutics shares are held by insiders. Comparatively, 10.6% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryTG Therapeutics beats Janux Therapeutics on 9 of the 17 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-17.3217.7428.9323.80Price / Sales131.64309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book1.218.488.255.54Net Income-$68.99M-$55.06M$3.25B$259.97M7 Day Performance-9.24%-3.99%-3.75%-4.67%1 Month Performance-3.99%8.53%2.99%3.29%1 Year Performance-39.22%6.51%25.34%17.92% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.3971 of 5 stars$23.56-1.9%$91.89+290.0%-39.2%$1.39B$10.59M-17.3230Positive NewsUpcoming EarningsTGTXTG Therapeutics4.1523 of 5 stars$35.99-2.5%$43.80+21.7%+89.3%$5.86B$329M149.96290Positive NewsUpcoming EarningsNUVLNuvalent3.2094 of 5 stars$81.94+0.7%$119.60+46.0%+6.3%$5.85BN/A-18.6740Positive NewsCRSPCRISPR Therapeutics2.8186 of 5 stars$63.75-1.6%$71.31+11.9%+9.7%$5.59B$37.31M-14.10460News CoverageUpcoming EarningsAnalyst RevisionGap UpRYTMRhythm Pharmaceuticals3.5487 of 5 stars$85.68-0.9%$91.93+7.3%+99.8%$5.50B$130.13M-30.49140Upcoming EarningsInsider TradeLNTHLantheus4.6714 of 5 stars$72.41-0.7%$131.20+81.2%-27.7%$5.05B$1.53B20.57700News CoverageUpcoming EarningsAnalyst RevisionAXSMAxsome Therapeutics4.8178 of 5 stars$100.39-0.4%$172.33+71.7%+22.0%$4.96B$385.69M-17.40380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.81B$516.72M0.00N/AGap DownPCVXVaxcyte2.2239 of 5 stars$35.87-2.1%$136.50+280.5%-56.4%$4.73BN/A-8.99160News CoveragePositive NewsUpcoming EarningsMRUSMerus3.0489 of 5 stars$65.59-1.8%$86.40+31.7%+25.8%$4.62B$36.13M-16.0837News CoverageUpcoming EarningsCYTKCytokinetics4.0874 of 5 stars$36.63-1.5%$70.92+93.6%-35.8%$4.44B$18.47M-6.92250News CoverageUpcoming EarningsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies TGTX Competitors NUVL Competitors CRSP Competitors RYTM Competitors LNTH Competitors AXSM Competitors TLX Competitors PCVX Competitors MRUS Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
